anti-HLA-A*02:01/p53 R175H bispecific T-cell engager CLSP-1025
An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176) bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific antigen CD3epsilon (CD3e), with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02:01/p53 R175H bispecific TCE CLSP-1025 specifically targets and binds to CD3 on cytotoxic T lymphocytes (CTLs) with its anti-CD3 domain and the p53(R175H)168-176 mutant peptide bound to HLA-A*02:01 expressed on tumor cells with its anti-peptide HLA (pHLA) domain. This activates and redirects CTLs to HLA-A*02:01/p53 R175H-expressing tumor cells, which results in the CTL-mediated cell death of these p53 R175H-expressing tumor cells. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
| Synonym: | anti-p53 R175H T-cell engager CLSP-1025 anti-p53 R175H TCE CLSP-1025 anti-p53 R175H/CD3 fusion protein CLSP-1025 bispecific T-cell engager anti-HLA-A*02:01/p53 R175H CLSP-1025 bispecific TCE CLSP-1025 p53 R175H/HLA-A*02:01-specific T-cell engager CLSP-1025 pHLAre (TM) CLSP-1025 precise HLA redirecting engager CLSP-1025 |
|---|---|
| Code name: | CLSP 1025 CLSP-1025 CLSP1025 |